{"name":"FutureChem","slug":"futurechem","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"[F-18]Florastamin","genericName":"[F-18]Florastamin","slug":"f-18-florastamin","indication":"Hypercholesterolemia","status":"phase_3"}]}],"pipeline":[{"name":"[F-18]Florastamin","genericName":"[F-18]Florastamin","slug":"f-18-florastamin","phase":"phase_3","mechanism":"Florastatin is a radiolabeled version of florastatin, a statin used to lower cholesterol levels.","indications":["Hypercholesterolemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPbkNzcTQxZGNrbTNVZTRjaXM3U0l5ejRaSTM0bFAweGJQbVkwT2MtMkhxWHplQXlYTUVERU9HQUFqNllHNndvSkM3TjNDSHpJci05SXFuMzlETTFpZGF0aE1hMWJxa2RXSzJESXBOU0JBcEtyLUI4RlBlb3BDLUxWRtIBlAFBVV95cUxOOVcxNDh5OHAxTFE4WjRiemNBbU1xckRRVWNnS3gweW1fbHBNODNxVjlsUVhHNjhPUDlwSEtMNS1BZ2pnSHhHdXFnQWdFYUpRX0hOU194d0VlQU1tZjR4MzZIZ0JfcHl2NEg2RjRsZWR2NC1UUVJ3cDVFUGpSV3pfbDZMQ3dEX1ZTVVhQR2hBRVh6bjNV?oc=5","date":"2026-01-26","type":"pipeline","source":"Chosunbiz","summary":"Big pharma court Korea RPT developers as Novartis leads radiopharma push - CHOSUNBIZ - Chosunbiz","headline":"Big pharma court Korea RPT developers as Novartis leads radiopharma push - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBPV2dpMENHdE9DMHlOUjBaM0ZmN0RZbGs5bHhNNzVFMHlZaUYxbFdJX25OOHhjZXhxZDhVYWRTdzNUUGZ5NVdvbkpwNHRfUm16WWZZY1ZHb0tOaUZoNndaZ2pLOEVnNmhZalg1amdB0gFyQVVfeXFMTVVnWlBmWWJna0tXYkdVeXV6ZE5aaXdWZldITzB3MDBXYVVFNEVadV9rOVVXVzB6amo0Tm9POFF4UllMUEdpb294VFJjYlpaZWUzMlZnaHFsV1FzNkhEY0NLeDh0MVFmb0t1WjctaHVfZkx3?oc=5","date":"2025-09-17","type":"regulatory","source":"koreabiomed.com","summary":"FutureChem’s prostate cancer drug FC705 shows phase 2 progress, eyes fast-track approval - koreabiomed.com","headline":"FutureChem’s prostate cancer drug FC705 shows phase 2 progress, eyes fast-track approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE45QmJ3STAtWDk1Q0lsdHZERWFmWlZ2SjktaTFQeXZWWVVVUE9KM2doTm4xWDdoMnRrSVI5MFM3RmFzUTI3SzhVNXlmbGltVXR5b01hdnFPcmQzeV93XzBzWlBrbDROTmRJM2pwZGlB0gFyQVVfeXFMUC1nV0o0WlVjOXJ0Q19NWDhNSGN3VHRna0xtQlBfYlJ4d0kyMTdSSHUwbTA2T0wtdmU5WXZ4U1hPMng1SFhRdEtja3otcllUdUdvQnFsVXgzWnRtNG54WE9aRUlSazhzeGp0dWRSZ3FnODBn?oc=5","date":"2025-09-08","type":"regulatory","source":"koreabiomed.com","summary":"FutureChem's radiopharmaceutical wins MFDS approval for phase 3 prostate cancer trial - koreabiomed.com","headline":"FutureChem's radiopharmaceutical wins MFDS approval for phase 3 prostate cancer trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNbjJSZEp5d0VfMTNjUVZSclJaLWg2TU9vWUhhVDBZaG83cC11bFpYbjlyMFJGSi1vVW5TOWY1TldUU1pwMHQzUUU5N0RoSktOblZsak1xZHJxbHVSZWc5anNmSEJPdEViM3FIcUZnVkhNWE9TcmhLVUl6TlhZRnlFbjliOXpzdlc1ZVpwTXJpZ3lRTUhlN2JGUU9JbWVVdDd2a3VlNXNMNzBMdEEtNmVweVZsc0hGcUdtdHc?oc=5","date":"2025-08-02","type":"pipeline","source":"BioSpectrum Asia","summary":"APAC building on enough supply network for radiopharmaceuticals - BioSpectrum Asia","headline":"APAC building on enough supply network for radiopharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9wRXNJb2ZXUFNjWF9qQmJERlZyMmhiVkNrZzRJbkpXOG5tcWJWblI1T21MUnlDV01TTGhWSmRpOWJCemZTZzRxM1NKUTJPb0FvcTc4VVRCSUY2Z0c2YmZLTHBYdFRiYzY1UFBfeGRB?oc=5","date":"2025-07-10","type":"trial","source":"koreabiomed.com","summary":"FutureChem's FC303 meets phase 3 goals, setting stage for 1st Korean-developed PSMA PET imaging agent - koreabiomed.com","headline":"FutureChem's FC303 meets phase 3 goals, setting stage for 1st Korean-developed PSMA PET imaging agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5OQVBXM19nbVNGeVVfUXdfQUZfSWVPbzB4bnlQT0R1OUJETmZkUl8xb3phcGxVSTg5UmEzbDJfbkFWYTZsRkFLSWRqVjlDcVk5ZnpiWHBaSFc1eW5rZ0pRbkZ1SHpjdS1YZXpEbkp30gFyQVVfeXFMTnZDVGoyTjRROGN4enpvRU4tYnNlUk9ITkhtTlZ6M0ZrbUo1akswRlF2eTF3ZXhOVkxCTnFXTnROYzdaN0dMeGVYb0RfbXZqLTVHZ3JHbExzS3FKMktMV2c0NFdkY1lBYmxqSWcyV3pZRndR?oc=5","date":"2025-03-11","type":"trial","source":"koreabiomed.com","summary":"FutureChem moves new prostate cancer drug into phase 3 trial in Korea - koreabiomed.com","headline":"FutureChem moves new prostate cancer drug into phase 3 trial in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNNDZYTGJpb3FGS09zNXpITEtRRnhoN1BNNXNON3hubXdWZVNkc2JJOEtvYURpemxiOUY4LU9yRzhPQ21Wdml4RGJpODVUY2phR09Sc2dmVHd1cG4wa2Y2ZWdHck82X1p2djhuYjFibGc1V2Y1YjBFMnBONkJ5N0d5UtIBlAFBVV95cUxNaWpiLWoxNXVvMkhZdk5YNnpLdUVUN3k4TnVkS2NMR2NJNW1jOVhIV0pZN25QajhZWEdtY0tzQkJsMFoyd0NBaUJ5X1R1WTdJR2RaZlBJcnVtLWJsdnphQ2VVbjk4by01bTVTYTBNZUQyQ1kxNjdvbXg0MXdWT1Nic0J1ekhwVTV5bTV6TGNvYjg4Q3lu?oc=5","date":"2025-02-19","type":"pipeline","source":"Chosunbiz","summary":"Korea boosts radioactive pharmaceuticals market as Novartis leads growth - CHOSUNBIZ - Chosunbiz","headline":"Korea boosts radioactive pharmaceuticals market as Novartis leads growth - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBINGstN1FmbjRqcGlHMmdBUzI4Ry1zTEQ0SjBmQ1d1MHVOamZSNkx3bzY5TUFRc09RWlNQc2dQX1d1QUpiR2xHUWpjV2FLc0N4Y192UjBYSngzRTVJQVk0R2RaZk5mZDBMRjhvVTl30gFyQVVfeXFMT2ptMzJPZWx4QXVjR2ZJaTVxT0NGX2lxSldwSDU1X3JzRV81c0tfcWdMZlJtaThZQWJvbHVnaUNJcU5tM3JXOGt1RXNBSmxfb1l1ZFRWV3lsOUd3RF9rc2RsUTloUElDZmlNQ2JROXV5ejlB?oc=5","date":"2025-01-14","type":"pipeline","source":"koreabiomed.com","summary":"Korea’s radiopharmaceutical market heats up as companies vie for global leadership - koreabiomed.com","headline":"Korea’s radiopharmaceutical market heats up as companies vie for global leadership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5aRkJhbmdDOHRVUDE2Nlg2WUsxcHpQX0w1TUFfTFByeXpnTGd1WXRtZWFTQkpKdnVBd1A1ZXRiMGdFQXV0RmNwalNvUllfcDhfZVF0MHB0R2g0YnRpeWkwcmRtSlRhdHlMZ241SzFR0gFyQVVfeXFMTXBFZGZzZFdYR2lySWdfVlg4YUctRGxaZGI2c2pIZnFWVllXU2JpQno2eTZfTVEyVUZzR1MxLUtRd2NTeFF6cDZ1Tm83T1hFTGtKYUVGVFVpOWNRTW1tZm52bDA0MjRsZlB6QzEzeU1JSmZn?oc=5","date":"2023-09-07","type":"trial","source":"koreabiomed.com","summary":"FutureChem releases phase 1 results for prostate cancer drug in US trials - koreabiomed.com","headline":"FutureChem releases phase 1 results for prostate cancer drug in US trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1oODQ5N1pIdTktYkdIZFpSb3lLQno3dEhjUkd2MWFsRnVwYzBGa183ZnFlWk9GSFJzY3FSWUxJTGx1dXlNZ0U3RVMxZHU2SGpKMFJSaUFxWHNTR0VTWUVncGFoam5LQkxEU19qYTVR?oc=5","date":"2023-06-16","type":"regulatory","source":"KED Global","summary":"Daehwa Pharm applies for approval of anti-dementia patch in China - KED Global","headline":"Daehwa Pharm applies for approval of anti-dementia patch in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1UNVplTngwYVRDNGdldHM1OVR3OWNDSVlZMVI3ZW9DaEhvQVczN3VMOHFscFhvY040Z2NKcENUVFRNUnBWZVQtdHc4bkhldXM3WHRmSG5KYWkwM3NLUmpXVW5sUFZjTE9FNGhyMzhB?oc=5","date":"2023-03-17","type":"regulatory","source":"KED Global","summary":"S.Korea's FutureChem gets approval for phase 3 clinical trials in China - KED Global","headline":"S.Korea's FutureChem gets approval for phase 3 clinical trials in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNVkpMWk11MVZOZEFjUUhwN0x0UVFtNDVpZmFmc294YkpyS2FxZlJUdXQ1TzUzQ2pNZGpDQjVNc291T3dCdlQ2U25RNHJXTW9HNVJwMWlWZk9GV0lnRGhBRW04QnYzQW9XWGdoNXQ2WXYxZzN3M2hfblItZkZ5TGVhTHNRMFE1QUhMc1ZjaGNUSTdSTl9xNUxWTEZDX0JaZw?oc=5","date":"2022-11-22","type":"pipeline","source":"Contract Pharma","summary":"Monrol and FutureChem Sign Clinical Supply Contract - Contract Pharma","headline":"Monrol and FutureChem Sign Clinical Supply Contract","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}